Absci Corporation’s ABSI share price has surged by 5.86%, which has investors questioning if this is right time to sell.

Absci gained on animal testing phaseout news, but the change has limited near-term impact on its investment case. Read why ...

Absci Corporation stock has dropped since January, driven by weak earnings and broader biotech sector pressures. Despite weak financials, Absci's internal pipeline, including ABS-101 and ABS-201 ...

Washington’s life sciences industry injected a $41.2-billion impact into the state’s economy in 2023 — a 6.2% gain over 2022 ...

KeyBanc raised the firm’s price target on Absci (ABSI) to $9 from $5 and keeps an Overweight rating on the shares. Into Q1 earnings, the firm believes the focus for the HCIT sector will be on ...

Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates ...

Shares of NASDAQ ABSI opened at $3.09 on Wednesday. Absci has a 52 week low of $2.01 and a 52 week high of $6.33. The company has a quick ratio of 5.63, a current ratio of 5.63 and a debt-to ...

7 analysts have expressed a variety of opinions on Absci ABSI over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table encapsulates their recent ...

In a report released today, Scott Schoenhaus from KeyBanc maintained a Buy rating on AbSci (ABSI – Research Report), with a price target of ...

VANCOUVER, Wash. and NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report ...

Absci (NASDAQ:ABSI – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at Needham & Company LLC in a research note issued to investors on Wednesday ...